Citigroup Reiterates Buy Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reiterated by investment analysts at Citigroup in a report issued on Thursday,Digital Look reports.

A number of other research firms have also recently issued reports on HIK. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 195 price target on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd. Jefferies Financial Group upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Berenberg Bank restated a “buy” rating and set a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hikma Pharmaceuticals currently has an average rating of “Buy” and an average price target of GBX 1,687.

Hikma Pharmaceuticals Stock Up 0.6%

Hikma Pharmaceuticals stock opened at GBX 1,561 on Thursday. The stock has a market capitalization of £3.28 billion, a PE ratio of 8.62, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 2,052. The business has a 50 day simple moving average of GBX 1,492.24 and a 200-day simple moving average of GBX 1,449.18. The company has a debt-to-equity ratio of 61.84, a current ratio of 1.82 and a quick ratio of 1.27.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.